Early Glycan Screening: Key to High-Quality Biologics Development, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn about the importance of early glycan screening for ensuring biologic quality, and how automation reduces time-to-insight and improves workflow efficiency. The featured speakers will share real-world applications and results from glycan screening success. Attendees will learn how to integrate automated glycan profiling into cell line development (CLD) labs.

Early glycan screening is a cornerstone for ensuring long-term biologic quality and accelerating decision-making in cell line development (CLD). Glycan profiles, as a critical quality attribute, play a pivotal role in therapeutic efficacy, stability and safety.

This webinar explores how high-throughput glycan screening integrates into the broader Solentim ecosystem for CLD automation, reducing manual effort while providing scientists with rapid, actionable clone data.

Attendees will learn from different case studies on biosimilars and glycan-engineered antibodies, discovering how automated workflows improve accuracy and efficiency while eliminating unnecessary clone progression. Whether new to CLD or optimizing existing workflows, this webinar offers practical strategies to drive biologic excellence through early glycan insights.

Register for this webinar today to discover how early glycan screening is revolutionizing cell line development by ensuring biologic quality and accelerating decision-making.

Join Sebastian Giehring, CEO, PAIA; and Andrea Gough, Senior Director, Solentim Portfolio, for the live webinar on Tuesday, March 4, 2025, with Broadcast 1 ­- UK & Europe at 1pm GMT (2pm CET) and Broadcast 2 - North America at 2pm PST (5pm EST).

For more information, or to register for this event, visit Early Glycan Screening: Key to High-Quality Biologics Development (Broadcast 1) or Early Glycan Screening: Key to High-Quality Biologics Development (Broadcast 2).